LIGAND PHARMACEUTICALS INC (LGND) FY2025 10-K Annual Report
LIGAND PHARMACEUTICALS INC (LGND) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 27, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
LIGAND PHARMACEUTICALS INC FY2025 10-K Analysis
Business Overview
- • Core business model: biopharmaceutical royalty company focused on capital deployment and licensing for diversified royalty streams from mid- to late-stage products
- • New emphasis on NITRICIL platform acquired via Novan in 2023, supporting multiple royalty-bearing products including FDA-approved Zelsuvmi
- • Strategic refinement since 2022 to a high-margin, low-infrastructure model after spinoffs of OmniAb, Pelican Expression, and Pelthos Therapeutics
- • Invested $50 million in Castle Creek's D-Fi Phase 3 gene therapy and $25 million in Orchestra BioMed late-stage cardiology programs in 2025
- • Expanded royalty portfolio to 12 major commercial royalties and over 90 additional programs, showing growing diversity and disciplined capital allocation
Management Discussion & Analysis
- • Revenue and profit details not provided in the excerpt
- • No segment performance data disclosed in the excerpt
- • No cash flow, buybacks, dividends, or capex information included
- • No forward-looking statements or guidance mentioned
Risk Factors
- • Regulatory risk: Section 162(m) limitation increased tax expense by $3.9 million (156%) in 2024 affecting effective tax rate
- • Macroeconomic threat: $460 million 2030 Notes issued in August 2025 increases interest expense by $1.7 million (55%) vs prior year
- • Operational risk: Deconsolidation of Novan acquisition payments from July 1, 2025 impacts interest accrued and financial reporting
- • Market disruption risk: Unrealized fair value loss $5.1 million on Viking common stock in 2025 vs $9.0 million gain in 2024
- • Financial risk: Concentration in equity method investments, e.g., $90.7 million gain from Pelthos stock fair value changes in 2025
LIGAND PHARMACEUTICALS INC FY2025 Key Financial MetricsXBRL
Revenue
$268M
▲ +60.4% YoY
Net Income
$124M
▲ +3186.6% YoY
Operating Margin
15.3%
▲ +2882bp YoY
Net Margin
46.4%
▲ +4884bp YoY
ROE
12.2%
▲ +1272bp YoY
Total Assets
$1.6B
▲ +65.7% YoY
EPS (Diluted)
$6.13
▲ +2886.4% YoY
Operating Cash Flow
$49M
▼ -49.1% YoY
Source: XBRL data from LIGAND PHARMACEUTICALS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on LIGAND PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.